Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Scott K. Smith is active.

Publication


Featured researches published by Scott K. Smith.


Journal of the American Chemical Society | 2008

Isolation and structure elucidation of parnafungins, antifungal natural products that inhibit mRNA polyadenylation.

Craig A. Parish; Scott K. Smith; Kathleen Calati; Deborah L. Zink; Kenneth E. Wilson; Terry Roemer; Bo Jiang; Deming Xu; Gerald F. Bills; Gonzalo Platas; Fernando Pelaez; Maria Teresa Diez; Nancy N. Tsou; Arlene E. Mckeown; Richard G. Ball; Mary Ann Powles; Lai Yeung; Paul A. Liberator; Guy H. Harris

The Candida albicans Fitness Test, a whole-cell screening platform, was used to profile crude fermentation extracts for novel antifungal natural products with interesting mechanisms of action. An extract with intrinsic antifungal activity from the fungus Fusarium larvarum displayed a Fitness Test profile that strongly implicated mRNA processing as the molecular target responsible for inhibition of fungal growth. Isolation of the active components from this sample identified a novel class of isoxazolidinone-containing natural products, which we have named parnafungins. These natural products were isolated as an interconverting mixture of four structural- and stereoisomers. The isomerization of the parnafungins was due to a retro-Michael ring-opening and subsequent reformation of a xanthone ring system. This interconversion was blocked by methylation of an enol moiety. Structure elucidation of purified parnafungin derivatives was accomplished by X-ray crystallography and NMR analysis. The biochemical target of these natural products has been identified as the fungal polyadenosine polymerase. Parnafungins demonstrated broad spectrum antifungal activity with no observed activity against gram-positive or gram-negative bacteria. The intact isoxazolidinone ring was required for antifungal activity. In addition, the natural products were efficacious in a mouse model of disseminated candidiasis.


Journal of the American Chemical Society | 2008

Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347

Chaowei Zhang; James Occi; Prakash S. Masurekar; John F. Barrett; Deborah L. Zink; Scott K. Smith; Russell Onishi; Sookhee Ha; Oscar Salazar; Olga Genilloud; Angela Basilio; Francisca Vicente; Charles Gill; Emily Hickey; Karen Dorso; Mary Motyl; Sheo B. Singh

Bacterial resistance to antibiotics, particularly to multiple drug resistant antibiotics, is becoming cause for significant concern. The only really viable course of action is to discover new antibiotics with novel mode of actions. Thiazolyl peptides are a class of natural products that are architecturally complex potent antibiotics but generally suffer from poor solubility and pharmaceutical properties. To discover new thiazolyl peptides potentially with better desired properties, we designed a highly specific assay with a pair of thiazomycin sensitive and resistant strains of Staphylococcus aureus, which led to the discovery of philipimycin, a new thiazolyl peptide glycoside. It was isolated along with an acid-catalyzed degradation product by bioassay-guided fractionation. Structure of both compounds was elucidated by extensive application of 2D NMR, 1D TOCSY, and HRESIFT-MS/MS. Both compounds showed strong antibacterial activities against gram-positive bacteria including MRSA and exhibited MIC values ranging from 0.015 to 1 microg/mL. Philipimycin was significantly more potent than the degradation product. Both compounds showed selective inhibition of protein synthesis, indicating that they targeted the ribosome. Philipimycin was effective in vivo in a mouse model of S. aureus infection exhibiting an ED50 value of 8.4 mg/kg. The docking studies of philipimycin suggested that a part of the molecule interacts with the ribosome and another part with Pro23, Pro22, and Pro26 of L11 protein, which helped in explaining the differential of activities between the sensitive and resistant strains. The design and execution of the bioassay, the isolation, structure, in vitro and in vivo antibacterial activity, and docking studies of philipimycin and its degradation product are described.


Journal of Natural Products | 2009

Antisense-Guided Isolation and Structure Elucidation of Pannomycin, a Substituted cis-Decalin from Geomyces pannorum

Craig A. Parish; Mercedes de la Cruz; Scott K. Smith; Deborah L. Zink; Jenny M. Baxter; Samantha Tucker-Samaras; Javier Collado; Gonzalo Platas; Gerald F. Bills; Maria Teresa Diez; Francisca Vicente; Fernando Pelaez; Kenneth E. Wilson

Antisense-based screening strategies can be used to sensitize a microorganism and selectively detect inhibitors against a particular cellular target of interest. A strain of Staphylococcus aureus that generates an antisense RNA against SecA,a central member of the protein secretion machinery, has been used to screen for novel antibacterials. Possible inhibitors of the SecA ATP-ase were selected with a high-throughput, two-plate agar-based whole cell differential sensitivity screen. After screening a library of over 115 000 natural products extracts with the SecA antisense strain, an extract of Geomyces pannorum was identified as providing increased activity against the sensitized strain as compared with the wild-type control. Bioassay-guided isolation of the active component from this fungal extract provided a new cis-decalin secondary metabolite, which we have named pannomycin.


Bioorganic & Medicinal Chemistry | 2009

Isolation, structure and biological activity of phomafungin, a cyclic lipodepsipeptide from a widespread tropical Phoma sp.

Kithsiri Herath; Guy H. Harris; Hiranthi Jayasuriya; Deborah L. Zink; Scott K. Smith; Francisca Vicente; Gerald F. Bills; Javier Collado; Antonio González; Bo Jiang; Jennifer Nielsen Kahn; Stefan Galuska; Robert A. Giacobbe; George K. Abruzzo; Emily Hickey; Paul A. Liberator; Deming Xu; Terry Roemer; Sheo B. Singh

We isolated a cyclic lipodepsipeptide, phomafungin, from a Phoma sp. The distinct antifungal activity of phomafungin in the crude extract was initially discovered by mechanistic profiling in the Candida albicans fitness test. The purified compound contains a 28 member ring consisting of eight amino acids and a beta-hydroxy-gamma-methyl-hexadecanoic acid, and displays a broad spectrum of antifungal activity against Candida spp., Aspergillus fumigatus and Trichophyton mentagrophytes with MIC of 2-8 microg/ml, and toxicity to mice at 25 mg/kg. The linear peptide derived from opening of the lactone ring was devoid of antifungal activity as well as toxicity. Phomafungin has been identified in a number of Phoma spp. collected from Africa and the Indian and Pacific Ocean islands.


Bioorganic & Medicinal Chemistry Letters | 2012

Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.

Sheo B. Singh; Michael A. Goetz; Scott K. Smith; Deborah L. Zink; Jon D. Polishook; Russell Onishi; Scott P. Salowe; Judyann Wiltsie; John J. Allocco; Janet M. Sigmund; Karen Dorso; Mercedes de la Cruz; Jesús Martín; Francisca Vicente; Olga Genilloud; Robert G.K. Donald; John W. Phillips

Emergence of bacterial resistance has eroded the effectiveness of many life saving antibiotics leading to an urgent need for new chemical classes of antibacterial agents. We have applied a Staphylococcus aureus fitness test strategy to natural products screening to meet this challenge. In this paper we report the discovery of kibdelomycin A, a demethylated congener of kibdelomycin, the representative of a novel class of antibiotics produced by a new strain of Kibdelosporangium. Kibdelomycin A is a potent inhibitor of DNA gyrase and topoisomerase IV, inhibits DNA synthesis and shows whole cell antibiotic activity, albeit, less potently than kibdelomycin. Kibdelomycin C-33 acetate and tetrahydro-bisdechloro derivatives of kibdelomycin were prepared which helped define a basic SAR of the family.


Tetrahedron Letters | 1998

COMPLESTATIN TO CHLOROPEPTIN I VIA A QUANTITATIVE ACID CATALYZED REARRANGEMENT. ABSOLUTE STEREOCHEMICAL DETERMINATION OF COMPLESTATIN

Hiranthi Jayasuriya; Gino Salituro; Scott K. Smith; James V. Heck; Steven J. Gould; Sheo B. Singh; Carl F. Homnick; M. Katharine Holloway; Steven M. Pitzenberger; Michael A. Patane

Abstract Complestatin and isomeric chloropeptin I are bicyclo hexapeptides isolated from a Streptomyces sp. Both of these compounds are inhibitors of gp120-CD4 HIV fusion activity. In this paper, we describe an efficient acid catalyzed conversion of complestatin to chloropeptin I, provide a plausible mechanism for this transformation, and unambiguously assign the stereochemistry of complestatin.


The Journal of Antibiotics | 2014

Isolation, structure elucidation and antibacterial activity of a new tetramic acid, ascosetin.

John G. Ondeyka; Scott K. Smith; Deborah L. Zink; Francisca Vicente; Angela Basilio; Gerald F. Bills; Jon D. Polishook; Charles G. Garlisi; Debra Mcguinness; Elizabeth M. Smith; Hongchen Qiu; Charles Gill; Robert G.K. Donald; John W. Phillips; Michael A. Goetz; Sheo B. Singh

The ever-increasing bacterial resistance to clinical antibiotics is making many drugs ineffective and creating significant treatment gaps. This can be only circumvented by the discovery of antibiotics with new mechanisms of action. We report here the identification of a new tetramic acid, ascosetin, from an Ascomycete using the Staphylococcus aureus fitness test screening method. The structure was elucidated by spectroscopic methods including 2D NMR and HRMS. Relative stereochemistry was determined by ROESY and absolute configuration was deduced by comparative CD spectroscopy. Ascosetin inhibited bacterial growth with 2–16 μg ml−1 MIC values against Gram-positive strains including methicillin-resistant S. aureus. It also inhibited the growth of Haemophilus influenzae with a MIC value of 8 μg ml−1. It inhibited DNA, RNA, protein and lipid synthesis with similar IC50 values, suggesting a lack of specificity; however, it produced neither bacterial membrane nor red blood cell lysis. It showed selectivity for bacterial growth inhibition compared with fungal but not mammalian cells. The isolation, structure and biological activity of ascosetin have been detailed here.


Journal of Natural Products | 2014

Discovery, Isolation, and Structure Elucidation of Dretamycin

Kenneth E. Wilson; Scott K. Smith; Rosemarie Kelly; Prakash S. Masurekar; Deming Xu; Craig A. Parish; Hao Wang; Debbie Zink; Julian Davies; Terry Roemer

The Candida albicans fitness test is a whole cell screening platform that utilizes a mixed-pool of C. albicans mutants, each of which carries a heterozygous deletion of a particular gene. In the presence of an antifungal inhibitor, a subset of these mutants exhibits a growth phenotype of hypersensitivity or hyposensitivity. Collectively these mutants reflect aspects of the mechanism of action of the compound in question. In the course of screening natural products a culture of Streptomyces sp. MS-1-4 was discovered to produce a compound, dretamycin, which yielded a fitness profile exhibiting significant hypersensitivity of the DRE2 heterozygote and hyposensitivity of the DIP5 heterozygote. Herein we report the production, isolation, and structure elucidation of dretamycin.


Chemistry & Biology | 2011

Discovery of Kibdelomycin, A Potent New Class of Bacterial Type II Topoisomerase Inhibitor by Chemical-Genetic Profiling in Staphylococcus aureus

John W. Phillips; Michael A. Goetz; Scott K. Smith; Deborah L. Zink; Jon D. Polishook; Russell Onishi; Scott P. Salowe; Judyann Wiltsie; John J. Allocco; Janet M. Sigmund; Karen Dorso; Suzy Lee; Stephen Skwish; Mercedes de la Cruz; Jesús Martín; Francisca Vicente; Olga Genilloud; Jun Lu; Ronald E. Painter; Katherine Young; Karen M. Overbye; Robert G.K. Donald; Sheo B. Singh


Journal of the American Chemical Society | 2002

Biosynthesis of Nodulisporic Acid A: Precursor Studies

Kevin M. Byrne; Scott K. Smith; John G. Ondeyka

Collaboration


Dive into the Scott K. Smith's collaboration.

Researchain Logo
Decentralizing Knowledge